TriCelX files ALS study for XytriX as third clinical program

TriCelX filed with the FDA to test its experimental biotherapeutic XytriX in ALS, expanding a single neurological strategy already in development for CTE and knee osteoarthritis. The company is seeking rare-disease status and expedited review as it tries to target inflammation-linked damage in a fatal disease with no cure.

Why it matters: - ALS has no cure, usually kills within two to five years after symptoms begin, and affects about 30,000 Americans. - TriCelX is trying to position XytriX as a treatment for the inflammation-driven damage that may help sustain both ALS and CTE, two brain diseases with no approved curative therapy. - The filing adds ALS as TriCelX’s third clinical program around one product, raising the stakes for a platform the company calls a single neurological strategy.

What happened: - TriCelX filed an application with the U.S. Food and Drug Administration to study XytriX in ALS. - The company is asking the FDA to grant ALS rare-disease status and to accept the program into an expedited pathway for life-threatening illnesses. - TriCelX describes the submission as a single continuous study that combines the three stages of drug development into one trial. - The ALS study is being run at the Baylor Scott and White Sports Therapy and Research Center in Frisco, Texas. - Dr. Abdul Baker, TriCelX’s chief medical and scientific officer, is the lead investigator.

The details: - XytriX is TriCelX’s experimental biotherapeutic made from signaling cells found in donated umbilical cord tissue. - The therapy is produced under TriCelX’s manufacturing protocols at its FDA-registered facility in Frisco, Texas. - The company says XytriX is already in development for chronic traumatic encephalopathy, with FDA clearance to proceed in June 2026, and knee osteoarthritis, where dosing is under way. - TriCelX says XytriX works by calming inflammation and supporting surviving neurons and synapses. - The company says the ALS program will use the same product, made from the same cell banks to the same standards, and delivered the same two ways as the CTE program. - No ALS patient will be treated until an independent safety board reviewing the CTE study has seen real results and cleared that dose. - TriCelX says the ALS study will start with 10 patients to assess safety and look for an early signal of benefit. - If the early signal appears, the study will move directly into a larger final stage without a pause. - Instead of a placebo arm, each patient will be compared with records from thousands of similar ALS patients in a database of more than 13,700 anonymized trial records. - The company says the comparison approach is meant to avoid placebo use in a fatal disease and still give a meaningful benchmark. - TriCelX says the trial design requires FDA agreement before moving from one stage to the next.

Between the lines: - TriCelX is tying ALS to CTE through shared neuroinflammation, not through a single disease-specific protein target. - The company’s logic is that repeated head impacts can trigger chronic inflammation in the brain and spinal cord, and that same inflammatory process appears in ALS. - That framing explains why a company already working on CTE is now moving into ALS. - The company is also aiming at populations with elevated ALS risk, including former NFL players and military veterans. - One study of 19,824 retired NFL players found ALS deaths at more than four times the rate of other American men. - Another study of 9.2 million veterans over 24 years counted 13,935 ALS cases. - A BMJ study from Mass General Brigham, Boston University and the Concussion & CTE Foundation found that at least one in four of 878 former NFL players who died from 2016 to 2021 had CTE at death. - Roughly 60% of the brain donors in that study met clinical criteria for dementia. - TriCelX is building relationships with former football players and military and veteran organizations as it advances the program.

What’s next: - TriCelX will wait for FDA action on its rare-disease and expedited-review requests. - The ALS study cannot begin treatment until the CTE safety board clears the dose based on actual data. - If the first 10 patients show a safety profile and early sign of benefit that meet preset targets, the company plans to expand the study into a larger final stage. - TriCelX says it will report results either way.

The bottom line: - TriCelX is betting that one inflammation-focused cell therapy can move from CTE into ALS, but the program still depends on FDA review and early clinical data before it can advance.